Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE)

NCT01470313 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01470313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01470313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE)
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2011
Completion date
November 30, 2013
Enrollment
28 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous lupus erythematosus